The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, ...

GSK has understood the game of access in Egypt earlier than other companies. By buying two successful local manufacturing facilities with their generic brands, GSK has better market access than ...

Before the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with ...

The NDA includes a combination of Blenrep with bortezomib plus dexamethasone (BorDex) or pomalidomide plus dexamethasone ...

Everything we covered on WTR over the past seven days, and all you need to know from the world of trademarks to set yourself up for the start of another busy week.

GSK Says mRNA Flu Shot Shows Promise in Boost for Pipeline GSK could beat Pfizer to market, says chief commercial officer Several drugmakers are betting on mRNA seasonal flu vaccines ...

Several Big Pharmas took home trophies at the annual Fierce Pharma Marketing Awards on Wednesday night. | Several Big Pharmas took home trophies at the annual Fierce Pharma Marketing Awards on ...

The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC ...

Earlier this year, Nucala rolled out the Let’s Get to It campaign, which opts for an “unapologetically candid” tone, ...

However, the earlier flops shook TIGIT players, with GSK and iTeos assessing “how best to proceed with additional clinical development” of their rival asset after a phase 3 Roche flop in 2022 ...

The TH HSV REC-003 trial was a phase 1/2 study that evaluated the reactogenicity, safety, immune response, and efficacy of GSK3943104, an HSV-targeted immunotherapy in individuals aged 18 to 60 years ...

DeepWell Digital Therapeutics received 510 (k) clearance from the FDA on its biofeedback software development kit for use in ...